Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, indications for monotherapy with 5-alpha-reductase inhibitors, such as finasteride and herbal drugs, were developed based on clinical and morphological changes in patients with benign prostatic hyperplasia.

This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.

This case report documents a 59-year-old man in Taiwan who developed breast cancer while undergoing finasteride therapy for benign prostate hyperplasia, marking a rare side effect.

This study found that in rats, combined treatment with finasteride and doxazosin altered epithelial cell behavior and matrix metalloproteinases activity, suggesting effects possibly mediated by TGF-β1 and androgen pathways.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.

Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.

Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.

This case study observed that unilateral oophorectomy may improve severe hyperandrogenism in adolescents with PCOS, even when imaging and SVS do not indicate neoplasm.

This article discusses the potential of finasteride as a chemopreventive agent for prostate cancer and highlights unresolved issues, but it reports no new research findings.

In this study, the combination of Serenoa repens extract with Phenolmicin P3 and Bosexil suppositories significantly improved lower urinary tract symptoms and decreased PSA levels in patients with benign prostatic obstruction-related symptoms.

This study found that the active use of androgen deprivation therapy was not associated with a reduced risk of death in prostate cancer patients with COVID-19.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

This review reports that combination therapy with 5α-reductase inhibitors and α1-receptor blockers does not appear to benefit patients with benign prostatic hyperplasia and prostate volumes up to 40–45 ml, but may be more effective for larger prostate volumes.

This article summarizes various studies in adult urology, including those on diagnostic techniques for prostate cancer and outcomes of different treatments for benign prostatic hyperplasia, but reports no new findings.

This study found that combination therapy with doxazosin and finasteride was more effective in preventing the clinical progression of benign prostatic hyperplasia than either drug alone.

This review examines the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia, noting moderate positive effects without complete cure and the need for further research to understand drug mechanisms and pathogenesis.

In this study of BPH patients with testosterone deficiency, the combination of TU and dutasteride reduced prostate volume and improved testosterone-related symptoms but was less effective for sexual function compared to TU alone, indicating caution in using dutasteride for those with sexual dysfunction concerns.

This review discusses the impact of COVID-19 on lower urinary tract symptoms and benign prostatic enlargement, noting altered patient care and management, but provides no new clinical results.

In this study, treatment with a 5a-reductase inhibitor increased CD8+ T cell infiltration in benign prostatic hyperplasia tissues, suggesting an impact on inflammatory responses.

This research reviewed existing literature to explore treatment options for androgen-dependent diseases, reporting that among prostate cancer therapies analyzed, the drug olaparib as monotherapy resulted in longer survival compared to the combination of apalutamide and abiraterone, though combined treatment efficacy differences were not statistically significant.

This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.

This study discusses a hypothesis that combining intermittent androgen ablation therapy with finasteride may enhance prostate cancer treatment, though new results from this approach are not yet available.

This article discusses the considerations and challenges surrounding a proposed large-scale trial on testosterone-replacement therapy in older men and reports no new results.

This article reviews research on the treatment of benign prostatic hyperplasia and suggests that 5-alpha-reductase inhibitors like finasteride may improve therapeutic outcomes, without providing new clinical results.

This study found that long-term use of 5α-reductase inhibitors is associated with improved overall survival in men with renal cell carcinoma, particularly those with low comorbidity not receiving surgery or systemic therapy, suggesting a potential role for androgen modulation in disease management.

In this study, the incidence of androgenic alopecia among transgender patients increased after starting masculinizing hormone therapy, with the highest incidence observed in the fourth year of treatment.

This study found that lower urinary tract symptoms in older men with benign prostatic hyperplasia negatively impact sexual function and mental health, suggesting the importance of early intervention to improve quality of life.

This study found that in beagles with benign prostate hyperplasia, finasteride treatment increased blood volume and decreased vessel leakiness in the prostate's parenchymal zone as shown by dynamic contrast-enhanced MRI.

This review discusses various treatments for benign prostatic hyperplasia, comparing medications like finasteride and terazosin, as well as surgical and placebo options, without presenting new clinical findings.